Novartis announced that after conducting an interim analysis from the CIRRUS-1 trial of CFZ533 (iscalimab), the company is discontinuing the study in kidney transplant patients.

Sarfez Pharmaceuticals announced approval by the U.S. Food and Drug Administration of the Virginia-based company’s New Drug Application for Soaanz, a once-a-day improved formulation of the loop diuretic torsemide.

The U.S. Food and Drug Administration greenlit AstraZeneca’s Farxiga (dapagliflozin) under priority review for the treatment of chronic kidney disease in patients at risk of progression with or without type 2 diabetes.

Shares of Calliditas Therapeutics soared in trading after the company announced positive Phase III data from a study of Nefecon in IgA nephropatjhy (IgAN), an autoimmune renal disease.

Alnylam Pharmaceuticals reported positive results for the ILLUMINATE-B Phase III clinical trial evaluating the RNAi therapeutic lumasiran in young children with primary hyperoxaluria type 1 (PH1).

Alexion Pharmaceuticals shuttered the company’s oral small molecule Factor D inhibitor program for a rare kidney disease following disappointing clinical data.